Prior authorization required — general PA requirement callout

Prior Authorization (PA) is required for many listed drugs in this formulary. Prescribers must obtain approval from Blue KC before the prescription can be filled for items marked PA. Claims for PA-designated products may be denied if authorization is not obtained prior to dispensing.

• PA applies to multiple drug classes and individual agents as shown in the formulary listings (PA flag).
• Prescribers may request exceptions or submit electronic PA requests via the Blue KC provider portal: www.BlueKC.com > Providers > Forms > Prior Authorizations for Medications.

Prior authorization required for selected drugs — PA examples

Prior authorization is specifically required for many selected drugs identified throughout the formulary (examples include certain analgesics, neurologic agents, metabolic/diabetes products, specialty agents, and biologics). When a drug in the formulary row is annotated with PA, approval is required before coverage.

• Analgesics: entries such as buprenorphine and tramadol ER are shown with PA flags in the listing.
• Neurologic / MS agents: fingolimod, glatiramer products, teriflunomide and others are marked PA in the formulary.
• Metabolic/Diabetes: select GLP‑1 agonists and other branded diabetes products (e.g., MOUNJARO, OZEMPIC, RYBELSUS) carry PA flags.
• Specialty/high‑cost agents and biologics (e.g., certain enzyme‑replacement or genetic disorder drugs) are marked PA and require prior approval.

Prior authorization required for listed MS and other agents

Multiple multiple sclerosis (MS) and other neurologic agents are annotated with PA and quantity limits in the formulary. Prior authorization must be obtained and supporting documentation of medical necessity may be required when requesting these agents.

• MS agents shown with PA include fingolimod, glatiramer acetate products, glatopa, and teriflunomide (all listed with PA; QL where indicated).
• Entries include both PA and QL flags — requests should include diagnosis, prior therapies tried, and dosing justification.

Prior authorization required for select products — PA/QL/ST flags

Prior authorization is required for select products across several therapeutic areas; these entries are flagged in the formulary and often paired with quantity limits (QL) and/or maintenance (M) or step therapy (ST) requirements. Obtain PA before dispensing to avoid claim denials.

• Antifungals and antivirals: posaconazole, voriconazole and others have PA flags.
• Antimigraine and pulmonary hypertension agents: some agents require PA and have QL limits.
• Insulins, GLP‑1 agents, and other diabetes supplies appear with PA and/or M/QL designations — check each formulary line for PA.
• Specialty products (G‑S) are frequently PA‑flagged.

Prior authorization — none listed in this index fragment

Some index fragments or portions of the formulary do not list prior authorization rules explicitly. In those segments the formulary is acting as an index or table of contents; absence of a PA flag in that fragment does not guarantee the product is PA‑free — always check the detailed listing for the drug.

• Index entries list page/location but may not include restriction flags; review the product detail row where PA/QL/ST are shown.
• When the formulary fragment shows no PA flag, confirm coverage via the provider portal or prior authorization tool.

Prior authorization references not included — index sections

Some index sections do not include prior authorization references or restriction flags. These are index‑only pages and must be cross‑referenced with the full formulary entries to determine PA status.

• Index pages (drug name → page references) do not display PA/QL/ST codes — see the corresponding formulary section for restriction details.

Syringe/Needle prescription requirement

Syringes and needles are covered only by prescription and only when used for medications requiring injection. Certain branded supplies (Techlite/Arkray) are covered at $0; other syringe/needle products may be covered only as non‑preferred brand and have specific restrictions.

• Syringes and needles require a prescription to be covered.
• Some pen needles and insulin syringe SKUs are marked ST, M, or OTC in the listing — confirm eligibility and any step‑therapy or maintenance limits before dispensing.

Restriction flags that may trigger denial

Restriction flags in the formulary (PA, QL, ST, M, ACA, OTC) indicate utilization controls that may trigger claim denials or require additional documentation. Entries marked with these flags must follow the corresponding prior authorization, quantity limit, or step therapy process.

• PA = Prior Authorization: provider must obtain approval prior to dispensing or the drug may not be covered.
• QL = Quantity Limit: the plan limits the amount covered; exceeding the limit may cause claim denial.
• ST = Step Therapy: trials of preferred agents may be required before coverage of the requested drug.
• M = Maintenance; ACA = Affordable Care Act preventive; OTC = Over the counter — these flags affect coverage and may interact with PA/QL/ST rules.

Step therapy/medical necessity denial risk

When entries include Step Therapy (ST) or Maintenance (M) flags, failure to meet step requirements or to document medical necessity may result in denial. Providers should document prior therapies tried and reasons for failure when requesting an exception or PA.

• Step therapy examples: gabapentin once‑daily formulations, pregabalin ER, and select neuropathic/neurology agents are annotated ST and QL in the listing.
• For diabetes and other chronic‑therapy products, ST and M flags appear on various branded agents — supporting documentation of prior trials is required for PA review.

No explicit authorization or denial rule — index only fragments

Some sections of the document are index‑only and do not contain explicit authorization or denial rules. Those sections are intended for navigation; providers must consult the full formulary entry for coverage rules and restriction details.

• Index entries list locations and do not replace the formulary rows that contain PA/QL/ST flags and documentation guidance.
• If an index fragment shows no PA or denial language, cross‑reference the detailed listing before taking action.

Quantity limit documentation

Quantity limits (QL) noted in the formulary imply documentation expectations. When a product is subject to a QL, prescribers should include intended dose, duration, and clinical rationale in PA or exception requests to support coverage above the standard limit.

• Examples: analgesics and antiemetics include QL specifications (EA/day, ML/day, EA per 365 days).
• Requests to exceed QL require documentation of medical necessity and prior treatment history.

Prior authorization / quantity limit handling

When a formulary entry includes PA and/or QL flags, follow Blue KC’s prior authorization and quantity‑limit handling procedures: obtain PA before dispensing when required, include required supporting clinical documentation, and confirm the approved quantity or refill frequency to avoid denials.

• Submit electronic PA via the Blue KC provider portal and include diagnosis, prior therapies, and rationale for the requested agent/quantity.
• Adhere to QL limits and ST requirements; if an exception is requested, provide documentation of trial and failure or clinical contraindication to preferred therapies.

Specialty‑pharmacy fill requirement for most specialty medications

Most specialty medications must be filled at a network Specialty Pharmacy (Optum Specialty Pharmacy) to be covered; prescribers and staff must ensure specialty prescriptions are routed to the network specialty pharmacy.

• Specialty medications are limited to a 34‑day supply and must be filled at the listed Specialty Pharmacy.
• Specialty Pharmacy offers care coordination, patient support, and handles specialty billing.